Results of KEYNOTE-716 trial may ‘level the playing field against melanoma’
Source: Healio, September 2021
Patients with resected stage IIB or stage IIC melanoma who received adjuvant pembrolizumab demonstrated a 35% reduction in risk for disease recurrence or death, according to results of the randomized phase 3 KEYNOTE-716 study.
